Der 1. Stufe des 8. Calls der Innovative Medicines Initiative wurde am 19. März 2013 geschlossen.  „Expressions of Interest“ (EoI) zu folgenden folgenden Topics  werden derzeit evaluiert:

Topics zu “New Drugs for Bad Bugs (ND4BB”):

• Topic 1C: Innovative Trial Design & Clinical Development (work package 6 of Topic 1)
• Topic 3: Discovery and development of new drugs combating Gram – negative infections

Topics zu "Developing an aetiology-based taxonomy for human diseases"

• Topic A: Approaches to develop a new classification for Systemic Lupus Erythematosus (SLE) and related connective tissue disorders and Rheumatoid Arthritis (RA)
• Topic B: Approaches to develop a new classification for neurodegenerative disorders with a focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD)

Topic "European induced pluripotent stem cell bank"

 

Unter www.imi.europa.eu/content/future-topics können Sie die Themenentwürfe für die 9. IMI-Ausschreibung aufrufen. Folgende Topics sind geplant:
 
Development of drug-drug-combinations
Developing an aetiological based taxonomy of human disease
Leveraging emerging technology for pharmacovigilance
European induced pluripotent stem cell bank
 
Der 9. IMI-Call soll im Oktober 2013 eröffnet werden.

 

Die IMI Research Agenda (Stand Juni 2011) bildet die Basis für die Themen der jeweiligen Ausschreibungen.

Die aktuelle IMI Forschungsagenda weist gegenüber der letzten Version von 2008 insbesondere folgende neue Elemente auf:
 
Erweiterung der bisherigen vier Säulen der Forschungsagenda (Safety, Efficacy, Knowledge Management, Education & Training) auf 7 vernetzte "Areas of Research Interest":

• Patients
• Diseases-Drug Efficacy
• Knowledge Management
• Strategies in R&D
• Development in Regulatory Framework
• Tools and Techniques
• Science Communication

Im Rahmen dieser “Areas of Research Interest” werden 10 „etablierte Forschungsprioritäten” und 8 neue "Key Research Priorities" definiert:

Established Key Research Priorities:

• Safety Sciences
• Increasing Practicability of Biomarkers and Biobanks
• Coping with Regulatory and Legal Hurdles
• Knowledge Management
• Science Communication
• Neuro-psychiatric Disorders/Brain Diseases
• Inflammatory and Immune-mediated Diseases
• Cancer
• Metabolic diseases including cardiovascular disease 
• Infectious disease

New Key Research Priorities:

• Pharmacogenetics and Taxonomy of Human Disease
• Rare Diseases and Stratified Therapies
• Systems Approaches in Drug Research
• Beyond High-Throupghput Screening - Pharmacological Interactions at the Molecular level
• API Technology (Drug Compound Development)
• Advanced Formulations
• Stem Cells for Drug Development and Toxicity Screening
• Integration of Imaging Techniques into Drug Research